Advent Capital Management’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Advent Capital Management’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,240	Closed	-$1.85K	–	243
2022 Q4	$1.85K	Hold	9,240	–	–	﹤0.01%	241
2022 Q3	$7K	Hold	9,240	–	–	﹤0.01%	223
2022 Q2	$5K	Hold	9,240	–	–	﹤0.01%	237
2022 Q1	$8K	Hold	9,240	–	–	﹤0.01%	268
2021 Q4	$21K	Hold	9,240	–	–	﹤0.01%	276
2021 Q3	$31K	Buy	+9,240	New	+$32.9K	﹤0.01%	241

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Advent Capital Management's DNA.WS Position: Q1 2023 in Review

Advent Capital Management sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q1 2023, closing a stake of 9,240 shares — an estimated $1.85K sold.

Advent Capital Management first reported a position in DNA.WS in Q3 2021 and held it in 6 quarters. The position peaked at $31K in Q3 2021. 40 funds tracked by Wall St. Rank hold DNA.WS as of Q1 2023.

Advent Capital Management reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q1 2023 after selling out during the quarter.
Advent Capital Management sold 9,240 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q1 2023, an estimated $1.85K.
Advent Capital Management first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 6 quarters.
Advent Capital Management's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $31K in Q3 2021.
40 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q1 2023.

Based on Advent Capital Management's 13F filing for Q1 2023, filed 12 May 2023.